Effect of recombinant Human Pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial
<h3>Importance</h3><p>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression.</p><h3>Objective</h3><p>To determine the effect of recombinant human pentraxin 2 vs plac...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 12, 2018
|
| In: |
The journal of the American Medical Association
Year: 2018, Jahrgang: 319, Heft: 22, Pages: 2299-2307 |
| ISSN: | 1538-3598 |
| DOI: | 10.1001/jama.2018.6129 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1001/jama.2018.6129 Verlag: https://jamanetwork.com/journals/jama/fullarticle/2681945 
|
| Verfasserangaben: | Ganesh Raghu, Bernt van den Blink, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden, Lawrence A. Ho, Marlies S. Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E. Antin-Ozerkis, Keith C. Meyer, Michael Kreuter, Hugues Santin-Janin, Geert-Jan Mulder, Brian Bartholmai, Renu Gupta, Luca Richeldi |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1698692692 | ||
| 003 | DE-627 | ||
| 005 | 20251023100014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200522s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2018.6129 |2 doi | |
| 035 | |a (DE-627)1698692692 | ||
| 035 | |a (DE-599)KXP1698692692 | ||
| 035 | |a (OCoLC)1341326298 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Raghu, Ganesh |e VerfasserIn |0 (DE-588)1186982365 |0 (DE-627)1666255513 |4 aut | |
| 245 | 1 | 0 | |a Effect of recombinant Human Pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis |b a randomized clinical trial |c Ganesh Raghu, Bernt van den Blink, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden, Lawrence A. Ho, Marlies S. Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E. Antin-Ozerkis, Keith C. Meyer, Michael Kreuter, Hugues Santin-Janin, Geert-Jan Mulder, Brian Bartholmai, Renu Gupta, Luca Richeldi |
| 264 | 1 | |c June 12, 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.05.2020 | ||
| 520 | |a <h3>Importance</h3><p>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression.</p><h3>Objective</h3><p>To determine the effect of recombinant human pentraxin 2 vs placebo on change from baseline to week 28 in mean forced vital capacity (FVC) percentage of predicted value.</p><h3>Design, Setting, and Participants</h3><p>Phase 2, randomized, double-blind, placebo-controlled trial conducted at 18 sites in 7 countries of eligible patients with IPF (N = 117; aged 40-80 years; FVC ≥50% and ≤90% predicted; ratio of forced expiratory volume in the first second/FVC >0.70; diffusing capacity for carbon monoxide [Dlco] ≥25% and ≤90% predicted; and distance of ≥150 m on the 6-minute walk test). Study period was August 2015-May 2017.</p><h3>Interventions</h3><p>Patients were randomized to receive either recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n = 77) or placebo (n = 39) for 24 weeks, and stratified by concurrent IPF treatment status.</p><h3>Main Outcomes and Measures</h3> | ||
| 700 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American Medical Association |t The journal of the American Medical Association |d Chicago, Ill. : American Medical Association, 1883 |g 319(2018), 22, Seite 2299-2307 |h Online-Ressource |w (DE-627)316017000 |w (DE-600)2018410-4 |w (DE-576)091019974 |x 1538-3598 |7 nnas |
| 773 | 1 | 8 | |g volume:319 |g year:2018 |g number:22 |g pages:2299-2307 |g extent:8 |a Effect of recombinant Human Pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis a randomized clinical trial |
| 856 | 4 | 0 | |u https://doi.org/10.1001/jama.2018.6129 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://jamanetwork.com/journals/jama/fullarticle/2681945 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200522 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |e 50000PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 12 | ||
| 999 | |a KXP-PPN1698692692 |e 3669930566 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1698692692","note":["Gesehen am 22.05.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Effect of recombinant Human Pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis","title":"Effect of recombinant Human Pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis","subtitle":"a randomized clinical trial"}],"language":["eng"],"person":[{"given":"Ganesh","roleDisplay":"VerfasserIn","role":"aut","display":"Raghu, Ganesh","family":"Raghu"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Michael","display":"Kreuter, Michael","family":"Kreuter"}],"relHost":[{"title":[{"subtitle":"JAMA","title_sort":"journal of the American Medical Association","title":"The journal of the American Medical Association"}],"origin":[{"dateIssuedDisp":"1883-","publisher":"American Medical Association","dateIssuedKey":"1883","publisherPlace":"Chicago, Ill."}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"disp":"American Medical AssociationThe journal of the American Medical Association","part":{"pages":"2299-2307","extent":"8","year":"2018","text":"319(2018), 22, Seite 2299-2307","issue":"22","volume":"319"},"recId":"316017000","note":["Gesehen am 23.08.2019"],"pubHistory":["1.1883 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"zdb":["2018410-4"],"eki":["316017000"],"issn":["1538-3598"]},"titleAlt":[{"title":"JAMA"}],"corporate":[{"display":"American Medical Association","roleDisplay":"VerfasserIn","role":"aut"}]}],"id":{"doi":["10.1001/jama.2018.6129"],"eki":["1698692692"]},"name":{"displayForm":["Ganesh Raghu, Bernt van den Blink, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden, Lawrence A. Ho, Marlies S. Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E. Antin-Ozerkis, Keith C. Meyer, Michael Kreuter, Hugues Santin-Janin, Geert-Jan Mulder, Brian Bartholmai, Renu Gupta, Luca Richeldi"]},"physDesc":[{"extent":"8 S."}],"origin":[{"dateIssuedDisp":"June 12, 2018","dateIssuedKey":"2018"}]} | ||
| SRT | |a RAGHUGANESEFFECTOFRE1220 | ||